Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3V7QO)

Drug Name

Vatelizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-2/beta-1 (ITGA2/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valetizumab	DMIKH67	Multiple sclerosis	8A40	Phase 2	[2]
SAR-339658	DMJ9RN8	Inflammatory bowel disease	DD72	Phase 2	[3]
Evatak	DMNMEAW	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
TCI15	DM06DI1	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02222948) Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis. U.S. National Institutes of Health.
2	Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
4	Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):719-24.